Genmab A/S (GMAB) jumps after updated Phase 2 petosemtamab data in metastatic colorectal cancer boosted confidence in its oncology pipeline. The move came on heavier-than-usual volume and followed recent positive clinical and analyst developments that strengthened the company’s growth outlook.
Genmab A/S (GMAB) jumped 15.98% after updated Phase 2 petosemtamab data in metastatic colorectal cancer gave investors a fresh clinical catalyst. The move was reinforced by above-average volume and recent positive pipeline developments, signaling stronger confidence in Genmab’s long-term oncology growth story, though valuation and trial risk remain important.
Genmab A/S (GMAB) jumps 15.98% to $51.81 at 10:00 a.m. ET on Oct. 28. Relative volume reached 1.8x the 200-day average, while a same-day petosemtamab update supplied a concrete clinical catalyst.
Key Takeaways
GMAB rose 15.98% to $51.81, with trading volume running 1.8x its 200-day average.
The primary catalyst was updated Phase 2 data for petosemtamab in metastatic colorectal cancer.
Genmab reported meaningful objective response rates from combinations with FOLFOX or FOLFIRI.
The company has a $31.86B market cap, $1.27 EPS, and a 35.17 P/E ratio.
The rally improves the pipeline story, but clinical-stage risk and a higher valuation call for disciplined position sizing.
Why Genmab A/S (GMAB) Jumps Today on Petosemtamab Data
The clearest catalyst is Genmab's Oct. 28 announcement of updated follow-up analyses from a Phase 2 petosemtamab trial in metastatic colorectal cancer. The company tested the drug with FOLFOX or FOLFIRI chemotherapy and reported meaningful objective response rates. directly connects the move to a clinical event.
Petosemtamab is an investigational IgG1 bispecific antibody that targets EGFR and LGR5. Its development spans metastatic colorectal cancer, head and neck squamous cell carcinoma, and non-small cell lung cancer. That breadth gives the asset more value than a single-indication program.
The volume confirms the market is treating the update as material. Relative volume of 1.8x the 200-day average is well above routine activity. In biotech, investors often reprice a company when new data changes the perceived odds of commercial success. Today's response fits that pattern.
Genmab Financials and Valuation After the GMAB Rally
GMAB enters the move with $1.27 in EPS and a 35.17 P/E ratio. Its market cap stands at $31.86B. The stock printed $51.81, above the listed 52-week high of $45.45 and well above the listed low of $23.62.
Recent earnings history provides useful support, though it is not a straight line. On Aug. 6, Genmab reported $0.54 in EPS against a $0.37 estimate, producing a 45.9% upside surprise. The company has beaten estimates in five of its last seven reported quarters.
However, Genmab also reported EPS of $0.13 against a $0.19 estimate in May and $0.21 against a $0.37 estimate in February. That record reflects the uneven timing of biotechnology revenue and development costs. Therefore, the petosemtamab data matters because it addresses future product value, not just the latest quarterly result.
Analyst sentiment adds another layer. On Oct. 27, J.P. Morgan upgraded GMAB to overweight from neutral and raised its target to DKr3,500 from DKr2,050. The firm cited positive November results expected from a late-stage petosemtamab trial in head and neck cancer. Separately, the analyst consensus target is $44.20, with a high of $58 and a low of $38.
Genmab's Oncology Pipeline Creates a Stronger Competitive Position
Genmab is more than a single-product biotech. The company markets EPKINLY and TEPKINLY for certain relapsed or refractory B-cell lymphomas. It also markets Tivdak for recurrent or metastatic cervical cancer. These products give Genmab an established commercial base while newer assets move through trials.
The partnered portfolio is also important. On Oct. 5, Genmab and AbbVie reported positive Phase 3 results for epcoritamab with R-CHOP in newly diagnosed diffuse large B-cell lymphoma. The combination produced a statistically significant progression-free survival improvement versus R-CHOP alone.
That result followed other petosemtamab developments. On Oct. 26, Genmab reported more than two years of median overall survival for petosemtamab plus pembrolizumab in first-line recurrent or metastatic head and neck cancer. Genmab also entered a clinical collaboration with Incyte to study petosemtamab with an investigational KRAS G12D inhibitor and chemotherapy in first-line metastatic colorectal cancer.
Together, these events support a broader pipeline-momentum narrative. Genmab's business combines royalties, profit sharing, co-development, and selected commercialization. The model can create durable value, but it also requires heavy spending across Phase 2 and Phase 3 programs.
How Investors Can Frame GMAB After This Clinical Re-Rating
The immediate case for GMAB rests on stronger pipeline validation. Updated colorectal cancer data, positive lymphoma results, and head and neck cancer progress arrived close together. That sequence supports a higher probability of multiple commercial products, which explains why the stock reacted so sharply.
Still, a strong data signal is not the same as regulatory approval. Petosemtamab must demonstrate durable efficacy, acceptable safety, and successful registrational results. Those risks matter more after a 15.98% one-day gain and a price above the listed 52-week high.
A disciplined approach separates the clinical thesis from the trading impulse. Existing holders can compare GMAB's position size with the 35.17 P/E ratio and the $44.20 analyst consensus target. New buyers should recognize that the market has already priced in a meaningful part of the improved pipeline narrative. Position sizing matters because clinical outcomes can move biotechnology shares in both directions.
Genmab A/S (GMAB) is gaining because updated petosemtamab data strengthened an already active oncology pipeline story. Above-average volume, recent analyst support, and positive epcoritamab results reinforce the move, but the valuation now leaves less room for disappointing clinical progress.
GMAB is up because Genmab released updated Phase 2 data for petosemtamab in metastatic colorectal cancer, and the results supported a stronger pipeline outlook. The stock also traded on 1.8x its 200-day average volume, confirming strong investor interest.
+Should I buy GMAB stock now?
The clinical update improves the investment case, but GMAB has already moved sharply and now trades at a higher valuation. Investors should treat it as a promising biotech name, but size positions carefully because trial outcomes can still change the story quickly.
+What drug caused Genmab's stock to jump?
The main catalyst was petosemtamab, Genmab’s investigational bispecific antibody. Updated follow-up data from a Phase 2 study in metastatic colorectal cancer helped drive the rally.
+Is Genmab still a risky biotech stock?
Yes. Even with encouraging data, petosemtamab still needs to prove durable efficacy, safety, and regulatory success in later-stage trials. That means the stock can remain volatile despite the positive news.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
▌The Full Report
Want the full picture on GMAB?
The analyst-grade research report — charts, grades, valuation, and price targets — in 10 minutes.
